目的:提供截至2015年12月非欧盟(EU)-28个欧洲委员会成员国的结直肠癌(CRC)筛查计划的最新信息。
方法:欧洲委员会的使命是保护和促进其47个成员国的人权。它的19个非欧盟成员国是阿尔巴尼亚,安道尔,亚美尼亚,阿塞拜疆,波斯尼亚和黑塞哥维那,塞族共和国,格鲁吉亚,冰岛,列支敦士登,摩尔多瓦共和国,摩纳哥,黑山,挪威,俄罗斯联邦,圣马力诺,塞尔维亚,瑞士,马其顿的FYR,土耳其,乌克兰(EU-19)。主要数据源为GLOBOCAN,IARC,WHO,EUCAN,NORDCAN,ENCR,CI5的第X卷,各个国家的部长级和公共卫生署网站,PubMed,EMBASE,一些网站和www的注册。cochranelibrary.com,Scopus,www.clinicaltrials.gov,www.临床试验登记。欧盟,研究门,谷歌和从筛查计划结果中提取的数据。
结果:我们的结果表明,欧盟28国和欧盟19国的流行病学数据质量差异很大。在发病率方面,只有30%的EU-19国家在数据质量方面排名较高,而在EU-28国家中,这一比例为86%。这同样适用于死亡率数据,因为52%的欧盟-19国家,而所有欧盟-28国家都处于较高的地位。对发病率数据收集方法的评估表明,只有32%的EU-19国家被发现在前三个质量类别中,而89%的EU-28国家。对于死亡率数据,与所有欧盟28个成员国相比,63%的欧盟19个国家排名最高。有趣的是,提供区域筛选节目的邻国的比较,例如,挪威的发病率和死亡率分别为38.9和13.0,瑞典为29.2和10.9,而在芬兰,在有国家组织方案的地方,分别为23.5和9.3。
结论:癌症筛查应被视为关键的医疗保健工具,还因为在筛查方面的投资可以保护人口中最弱的人,减轻癌症的社会负担,并降低所有类型的医疗保健成本,包括那些根治性手术,长期住院,和化疗。
OBJECTIVE: To provide an update on colorectal cancer (CRC) screening programmes in non-European Union (EU)-28 Council of Europe member states as of December 2015.
METHODS: The mission of the Council of Europe is to protect and promote human rights in its 47 member countries. Its 19 non-EU member states are Albania, Andorra, Armenia, Azerbaijan, Bosnia and Herzegovina, Republika Srpska, Georgia, Iceland, Liechtenstein, Republic of Moldova, Monaco, Montenegro, Norway, Russian Federation, San Marino, Serbia, Switzerland, FYR of Macedonia, Turkey, and Ukraine (EU-19). The main data source were GLOBOCAN, IARC, WHO, EUCAN, NORDCAN, ENCR, volume X of the CI5, the ministerial and Public Health Agency websites of the individual countries, PubMed, EMBASE, registries of some websites and the www.cochranelibrary.com, Scopus, www.clinicaltrials.gov, www.clinicaltrialsregister.eu, Research gate, Google and data extracted from screening programme results.
RESULTS: Our results show that epidemiological data quality varies broadly between EU-28 and EU-19 countries. In terms of incidence, only 30% of EU-19 countries rank high in data quality as opposed to 86% of EU-28 states. The same applies to mortality data, since 52% of EU-19 countries as against all EU-28 countries are found in the high ranks. Assessment of the method of collection of incidence data showed that only 32% of EU-19 countries are found in the top three quality classes as against 89% of EU-28 countries. For the mortality data, 63% of EU-19 countries are found in the highest ranks as opposed to all EU-28 member states. Interestingly, comparison of neighbouring countries offering regional screening shows, for instance, that incidence and mortality rates are respectively 38.9 and 13.0 in Norway and 29.2 and 10.9 in Sweden, whereas in Finland, where a national organised programme is available, they are respectively 23.5 and 9.3.
CONCLUSIONS: Cancer screening should be viewed as a key health care tool, also because investing in screening protects the weakest in the population, decreases the social burden of cancer, and reduces all types of health care costs, including those for radical surgery, long-term hospitalisation, and chemotherapy.